Compare Funko Inc (FNKO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

FNKO trades at $6.50, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% to $207.7M, and raised EBITDA guidance to $105M. Despite negative net margins, the stock trades at attractive valuations with P/S of 0.37 and EV/EBITDA of 6.7x. Recent management changes and product expansions signal strategic repositioning.

FNKO presents a turnaround opportunity with improving operational metrics and analyst consensus target of $7.58 (17% upside). Key risks include persistent negative profitability, high debt levels, and consumer discretionary sensitivity. The bullish technical setup combined with fundamental improvements supports cautious optimism for value investors seeking exposure to pop culture branding.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.